Clinical utility of circulating calprotectin to assist prediction and monitoring of COVID-19 severity: An Italian studyArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] 바이오마커, [키워드] Administered Admission assist Biomarker calprotectin Care chemiluminescent immunoassay circulating Circulating calprotectin clinical Cohort collected Concentration controls correlation COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 patients disease severity evaluate healthy individual ICU intubation Italian study median Patient positive airway pressure Respiratory Support risk risk assessment. Sample serological serum severity of COVID-19 Severity of disease significantly higher tested utility were used [DOI] 10.1002/jmv.28056 PMC 바로가기
Evaluation of response to different COVID-19 vaccines in vaccinated healthcare workers in a single center in IranArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 진단, [키워드] adenoviral-vectored vaccine Administered administration age anti-SARS-CoV-2 Anti-spike anti-spike antibody antibody Antibody Response average blood sample calculated center coronavirus disease Covaxin COVID-19 COVID-19 infection COVID-19 vaccine Cutoff ELISA evaluated Frequency healthcare worker individual Iran men Neutralizing antibodies neutralizing antibody neutralizing antibody. outcome Oxford/AstraZeneca pandemic participant participated positive proportion second dose significantly higher single center Sinopharm Sputnik V vaccination Vaccine Vaccines [DOI] 10.1002/jmv.28029 PMC 바로가기
Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice근육내 및 비강내 상동 프라임-부스트를 침팬지 아데노바이러스 기반 COVID-19 백신과 결합하면 마우스에서 강력한 체액성 및 세포성 면역 반응을 이끌어냅니다.Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Adenovirus adenovirus-based Adenovirus-vectored vaccine Administered antibody titres approach BALB/c mice booster Cellular immune response ChAdTS-S coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines cytokine decrease Efficacy elicit elicited evaluated followed by group highest homologous humoral IFN-γ IFN-γ ELISPOT IgA IgG immune immune responses immunogenicity intracellular cytokine staining intramuscular intramuscular vaccination intranasal intranasal. Meso Scale Discovery mice prime immunization priming protocol provide pseudovirus neutralizing antibody respiratory responsible SARS-CoV-2 serotype shown T-cell Response T-cell responses tested titre vaccination Vaccine variants vectored vaccine [DOI] 10.1080/22221751.2022.2097479 PMC 바로가기 [Article Type] Article
Serosurvey in SARS-CoV-2 inactivated vaccine-elicited neutralizing antibodies against authentic SARS-CoV-2 and its viral variantsArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome Administered Antibody neutralization BBIBP-CorV Beta booster vaccination circulating CoronaVac coronavirus Delta Eta Gamma humoral immune response immune immune response inactivated Inactivated vaccine individual Lineage lineages morbidity and mortality Mutation neutralization neutralization titer neutralize neutralized Neutralizing Neutralizing antibodies neutralizing antibody Neutralizing antibody response omicron reduce SARS-CoV-2 SARS-CoV-2 variant second vaccination serum sample significantly lower the SARS-CoV-2 vaccine dose variant viral variant Viral variants Viral variants. virus virus strain viruses wild-type [DOI] 10.1002/jmv.28049 PMC 바로가기
BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron wavesArticle Published on 2022-12-012022-11-16 Journal: Journal of Neurology [Category] COVID19(2023년), SARS, 변종, [키워드] Administered Affect Alpha BNT162b2 mRNA BNT162b2 mRNA vaccine contribute COVID-19 COVID-19 mortality COVID-19 vaccine develop disease General population Mild morbidity and mortality Myasthenia myasthenia gravis outcome Patient patients raise reduced risk Respiratory failure risk risk of COVID-19 Safety SARS-CoV-2 SARS-CoV-2 variants severe COVID-19 severe disease significantly higher vaccination Vaccine vaccine dose vaccine. [DOI] 10.1007/s00415-022-11303-8 PMC 바로가기
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialArticle Published on 2022-12-012022-10-06 Journal: The Lancet Regional Health - Western Pacific [Category] 진단, [키워드] acute respiratory syndrome Administered Adults adverse event AEs age analysis assessment assigned BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine China Chinese clinical trial Complete Completed conducted coronavirus COVID-19 development dose double-blind Efficacy and safety enrolled Follow-up geometric mean titer GMT GMTs Han Chinese healthy immune response immunogenicity immunogenicity endpoint Inc independent individual injection intramuscular Intramuscular injection investigators Laboratory parameters management messenger Messenger RNA Mild moderate mRNA vaccine Neutralising Antibodies neutralising antibody of BNT162b2 participant Participants pharmaceutical Placebo placebo-controlled trial randomisation randomised Randomly reactogenicity receive recipients recruited reduced remained reported resolved Result robust Safety SARS-CoV-2 SARS-CoV-2 variant SCR second dose sera serious AE seroconversion rate severity Shanghai Sponsor statisticians stratified T-cell Response the placebo group Tolerability Treatment Trial utilised vaccination vaccination. vaccine administration were blinded [DOI] 10.1016/j.lanwpc.2022.100586 PMC 바로가기 [Article Type] Article
COVID-19 intranasal vaccines: current progress, advantages, prospects, and challengesCOVID-19 비강내 백신: 현재 진행 상황, 이점, 전망 및 과제Review Published on 2022-11-302022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, SARS, 진단, [키워드] added Administered administration Antibody Response Cell-mediated immunity cellular immunity country COVID-19 COVID-19 pandemic COVID-19 vaccine disease highlight immune response Immunity induce injected injection intramuscular intranasal intranasal vaccine limit MOST mucosal mucosal immunity. Multiple nasal pandemic Prevent Protective Replication robust SARS-CoV-2 SARS-CoV-2 vaccine secretory IgA shown stimulate Vaccine Vaccines virus infection virus transmission [DOI] 10.1080/21645515.2022.2045853 PMC 바로가기 [Article Type] Review
Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccinesCoronaVac 및 ChAdox1 nCov-19(AZD1222) 백신으로 이종 프라임-부스트 백신 접종 후 면역원성 및 반응성Article Published on 2022-11-302022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, 진단, [키워드] 95% CI 95% confidence interval Administered age age and sex antibody assigned AZD1222 binding domain booster dose Care ChAdOx1 nCoV-19 Cohort cohorts Combination Concentration control group CoronaVac COVID-19 COVID-19 pandemic effective elicited enrolled finding geometric mean ratio GMR Health Heterologous heterologous prime-boost homologous immune response immunogenicity indicated mass participant primary endpoint prime-boost interval RBD reactogenicity robust Safe the median vaccination Vaccine vaccine administration vaccine combination. while [DOI] 10.1080/21645515.2022.2052525 PMC 바로가기 [Article Type] Article
An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2Article Published on 2022-11-082022-11-15 Journal: EMBO Molecular Medicine [Category] SARS, 변종, 유전자 메커니즘, 진단, [키워드] ACE2 Administered administration ameliorated Angiotensin-converting enzyme angiotensin-converting enzyme 2 antibody betacoronaviruses bind catalytic activity catalytically active Clinical use COVID-19 decoy demonstrated effective entry receptor High dose Host increased survival Infection Inflammation inoculated intravenous intravenously K18-hACE2 mice Loss Lung injury mechanism neutralization potency neutralize omicron Omicron variant persist PROTECT receptor receptor. reduced sACE2 SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants shown substrate target the SARS-CoV-2 therapeutic efficacy therapeutic potential Treatment virus [DOI] 10.15252/emmm.202216109 PMC 바로가기
Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatientsArticle Published on 2022-11-072022-11-16 Journal: BMC Infectious Diseases [Category] SARS, 변종, [키워드] 95% CI 95% confidence interval adjusted odds ratio Administered age Characteristics clinical trial Comorbidity COVID-19 COVID-19 outpatient death defined died early symptomatic COVID-19 effective Electronic health record health system Hospitalization Hospitalized immunocompromised status lack mAb mAbs Male sex Mild monoclonal antibodies monoclonal antibody monoclonal antibody treatment Mortality mortality data multicenter Neutralizing obesity Observational cohort study occurred pandemic Patient patients patients with COVID-19 positive Primary outcome real-world data reducing SARS-CoV-2 SARS-CoV-2 test SARS-CoV-2 vaccination SARS-CoV-2. Treatment Vaccine variants while [DOI] 10.1186/s12879-022-07819-z PMC 바로가기